These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 10051050)
1. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients. Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050 [TBL] [Abstract][Full Text] [Related]
2. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients. van Mourik ID; Thomson M; Kelly DA Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients. White M; Pelletier GB; Tan A; Jesina C; Carrier M J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770 [TBL] [Abstract][Full Text] [Related]
4. Neoral use in the cardiac transplant recipient. Valantine H Transplant Proc; 2000 May; 32(3A Suppl):27S-44S. PubMed ID: 10814748 [TBL] [Abstract][Full Text] [Related]
5. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Canadian Neoral Renal Transplantation Study Group Transplantation; 2001 Sep; 72(6):1024-32. PubMed ID: 11579295 [TBL] [Abstract][Full Text] [Related]
6. Neoral compared to Sandimmune is associated with a decrease in histologic severity of rejection in patients undergoing primary liver transplantation. Graziadei IW; Wiesner RH; Marotta PJ; Porayko MK; Dahlke LJ; Wilson SM; Steers JL; Krom RA Transplantation; 1997 Sep; 64(5):726-31. PubMed ID: 9311710 [TBL] [Abstract][Full Text] [Related]
7. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients. Akhlaghi F; Gonzalez L; Trull AK J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860 [TBL] [Abstract][Full Text] [Related]
11. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation]. Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420 [TBL] [Abstract][Full Text] [Related]
12. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group. Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802 [TBL] [Abstract][Full Text] [Related]
13. Longitudinal evaluation of the pharmacokinetics of cyclosporin microemulsion (Neoral) in pediatric renal transplant recipients and assessment of C2 level as a marker for absorption. Trompeter R; Fitzpatrick M; Hutchinson C; Johnston A Pediatr Transplant; 2003 Aug; 7(4):282-8. PubMed ID: 12890006 [TBL] [Abstract][Full Text] [Related]
14. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation. Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385 [TBL] [Abstract][Full Text] [Related]
15. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Keown P; Niese D Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620 [TBL] [Abstract][Full Text] [Related]
16. Neoral in de novo liver transplantation: adequate immunosuppression without intravenous cyclosporine. Levy GA; Rasmussen A; Mayer AD; Jamieson NV; Neuhaus P Liver Transpl Surg; 1997 Nov; 3(6):571-7. PubMed ID: 9404955 [TBL] [Abstract][Full Text] [Related]
17. Investigation of the pharmacokinetics of cyclosporine in patients following long-term administration after a kidney transplant: comparison of Neoral and Sandimmune. Takahara S; Ichimaru N; Kojima Y; Namba Y; Toki K; Shi Y; Yoshimura K; Matsumiya K; Nonomura N; Okuyama A Transplant Proc; 2004 Mar; 36(2 Suppl):456S-460S. PubMed ID: 15041387 [TBL] [Abstract][Full Text] [Related]
18. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Cantarovich M; Besner JG; Barkun JS; Elstein E; Loertscher R Clin Transplant; 1998 Jun; 12(3):243-9. PubMed ID: 9642517 [TBL] [Abstract][Full Text] [Related]
19. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral. Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479 [TBL] [Abstract][Full Text] [Related]
20. How to convert from traditional cyclosporine to the microemulsion formulation in stable renal transplant patients? Gaspari F; Perico N; Pisoni R; Anedda MF; Signorini O; Caruso R; Gotti E; Remuzzi G Clin Transplant; 1998 Oct; 12(5):379-90. PubMed ID: 9787945 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]